Literature DB >> 9933456

Genetic markers in clinically well defined patients with ulcerative colitis (UC).

G Bouma1, J B Crusius, M A García-González, B U Meijer, H P Hellemans, R J Hakvoort, G M Schreuder, P J Kostense, S G Meuwissen, A S Peña.   

Abstract

Results of genetic association studies in UC are conflicting. We propose that the power of candidate gene studies will increase when disease heterogeneity is taken into account. Phenotype frequencies of molecularly defined HLA-DR alleles, polymorphisms in the tumour necrosis factor-alpha (TNF-alpha), lymphotoxin-alpha (LT-alpha), IL-1 receptor antagonist (IL-1Ra) and IL-1beta genes were determined in 98 clinically well characterized UC patients with a mean period of follow up of 10 years, and ethnically matched healthy controls (HC). The alleles HLA-DRB1*0103 (phenotype frequency 6% versus 0.2%; P = 0.0002; odds ratio (OR) 27.6) and DRB1*15 (41% versus 26%; P = 0. 001; OR = 2.0, compared with HC) were associated with overall disease susceptibility. Subgroup analysis revealed that DRB1*15 was only increased in females (53% versus 24%; P < 0.0001; OR = 3.5), but not in males. With regard to disease localization, all DRB1*0103+ patients had extensive disease (P < 0.002; OR = 33.5), and DRB1*15 was found in 59% of females with extensive colitis (P < 0.0001; OR = 4.4). DRB1*0103 was significantly increased in patients undergoing colectomy (P < 0.0002; OR = 84). No association between overall disease susceptibility and the cytokine gene polymorphisms were found. Subgroup analysis revealed several significant associations, but most did not retain significance when corrected for multiple comparisons. However, a noticeable finding was that haplotype TNF-C was significantly associated with progression in extent of disease (P = 0.003, OR = 20.4). This study provides additional evidence for the role of DRB1 alleles in the susceptibility to UC, and supports the hypothesis that these alleles may determine the severity of the disease. The cytokine gene polymorphisms evaluated in this study do not seem to be strong risk factors for the overall disease susceptibility in UC, but may be involved in determining the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933456      PMCID: PMC1905167          DOI: 10.1046/j.1365-2249.1999.00797.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  A new restriction fragment length polymorphism of the human TNF-B gene detected by AspHI digest.

Authors:  S Ferencik; M Lindemann; B Horsthemke; H Grosse-Wilde
Journal:  Eur J Immunogenet       Date:  1992-12

2.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

Authors:  C O Jacob; Z Fronek; G D Lewis; M Koo; J A Hansen; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

4.  HLA antigens in ulcerative colitis: a study in the Sicilian population.

Authors:  C Caruso; P Palmeri; L Oliva; A Orlando; M Cottone
Journal:  Tissue Antigens       Date:  1985-01

5.  Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

6.  Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide.

Authors:  K Bendtzen; N Morling; A Fomsgaard; M Svenson; B Jakobsen; N Odum; A Svejgaard
Journal:  Scand J Immunol       Date:  1988-11       Impact factor: 3.487

7.  Analysis of HLA-DR2-associated polymorphisms by oligonucleotide hybridization in an Asian Indian population.

Authors:  N K Mehra; W Verduijn; V Taneja; J Drabbels; S P Singh; M J Giphart
Journal:  Hum Immunol       Date:  1991-12       Impact factor: 2.850

8.  HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression.

Authors:  S Futami; N Aoyama; Y Honsako; T Tamura; S Morimoto; T Nakashima; A Ohmoto; H Okano; M Miyamoto; H Inaba
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

9.  Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease.

Authors:  G Bioque; J B Crusius; I Koutroubakis; G Bouma; P J Kostense; S G Meuwissen; A S Peña
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

10.  Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production.

Authors:  G Messer; U Spengler; M C Jung; G Honold; K Blömer; G R Pape; G Riethmüller; E H Weiss
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

2.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

3.  Predictors of Outcome in Ulcerative Colitis.

Authors:  Matti Waterman; Jo Knight; Amreen Dinani; Wei Xu; Joanne M Stempak; Kenneth Croitoru; Geoffrey C Nguyen; Zane Cohen; Robin S McLeod; Gordon R Greenberg; A Hillary Steinhart; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

4.  Linkage of inflammatory bowel disease to human chromosome 6p.

Authors:  J Hampe; S H Shaw; R Saiz; N Leysens; A Lantermann; S Mascheretti; N J Lynch; A J MacPherson; S Bridger; S van Deventer; P Stokkers; P Morin; M M Mirza; A Forbes; J E Lennard-Jones; C G Mathew; M E Curran; S Schreiber
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 5.  Genetics of inflammatory bowel disease: the role of the HLA complex.

Authors:  Tariq Ahmad; Sara-E Marshall; Derek Jewell
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

6.  MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy.

Authors:  T R Orchard; A Dhar; J D Simmons; R Vaughan; K I Welsh; D P Jewell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

7.  Genetic Predictors of Benign Course of Ulcerative Colitis-A North American Inflammatory Bowel Disease Genetics Consortium Study.

Authors:  Uri Kopylov; Gabrielle Boucher; Matti Waterman; Claudia R Rivers; Mohini Patel; Judy H Cho; Jean F Colombel; Richard H Duerr; David Binion; Dermot P B McGovern; Phillip P Schumm; Steven R Brant; Mark S Silverberg; John D Rioux; Alain Bitton
Journal:  Inflamm Bowel Dis       Date:  2016-10       Impact factor: 5.325

Review 8.  Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning.

Authors:  Chang-Qing Zheng; Gang-Zheng Hu; Zhao-Shu Zeng; Lian-Jie Lin; Gin-Ge Gu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

9.  Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis.

Authors:  Marco M Hefti; David B Chessin; Noam H Harpaz; Randolph M Steinhagen; Thomas A Ullman
Journal:  Dis Colon Rectum       Date:  2009-02       Impact factor: 4.585

10.  Infliximab in ulcerative colitis.

Authors:  Avi Levin; Oren Shibolet
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.